LIfT BioSciences
June 22, 2026
Theater 3
Type: Company Presentation
Focus Area:
Immunology
LIfT BioSciences is pioneering a new class of immunotherapy for hard-to-treat cancers based on allogeneic Immuno Modulatory Alpha Neutrophils (IMANs)®. Our proprietary, long-lived IMANs harness neutrophils’ innate tumour-homing and infiltrating attributes, combined with their ability to directly kill cancer cells and safely orchestrate broader immune responses, offering a powerful and antigen-agnostic treatment option to overcome cancer resistance mechanisms, like suppressive tumour environment and immune evasion.
Company HQ City:
London
Company HQ State:
England
Company HQ Country:
United Kingdom
Year Founded:
2016
Lead Product in Development:
LIFT BioSciences is pioneering a new class of immunotherapy for hard-to-treat cancers based on allogeneic Immuno-Modulatory Alpha Neutrophils (IMANs)®. Our proprietary, platform harnesses neutrophils’ innate tumour-homing and infiltrating attributes, combined with their ability to directly kill cancer cells and safely orchestrate broader immune responses, offering a powerful and antigen-independent treatment option to overcome cancer resistance mechanisms, like suppressive tumour environment and immune evasion. Backed by deep neutrophil biology expertise and a scalable manufacturing process, LIfT’s platform represents a one-of-a-kind opportunity to reshape medicine and drive forward a pipeline of new therapeutics with major impact for patients.
CEO
Bo Rode Hansen
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
Spring 2027.
What is your next catalyst (value inflection) update?
First dose in man.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}